131 related articles for article (PubMed ID: 38407508)
21. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
[TBL] [Abstract][Full Text] [Related]
22. Dostarlimab, an anti-programmed death-1 monoclonal antibody, does not cause QT prolongation in patients with solid tumours: A concentration-QT analysis.
Kuchimanchi M; Dabrowski C; Lu S; Melhem M
Br J Clin Pharmacol; 2023 Jul; 89(7):2272-2282. PubMed ID: 36823349
[TBL] [Abstract][Full Text] [Related]
23. Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc-concentration modelling.
Hibma JE; Kantarjian HM; DeAngelo DJ; Boni JP
Br J Clin Pharmacol; 2019 Mar; 85(3):590-600. PubMed ID: 30536405
[TBL] [Abstract][Full Text] [Related]
24. Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study.
Zhang W; Smulders R; Abeyratne A; Dietz A; Krauwinkel W; Kadokura T; Keirns J
Clin Ther; 2013 Aug; 35(8):1150-1161.e3. PubMed ID: 23910665
[TBL] [Abstract][Full Text] [Related]
25. The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses.
Parkinson J; Sundell J; Rekić D; Nelander K; Ericsson H; Ebrahimi A; Dota C; Sunnåker M
Pharmacol Res Perspect; 2024 Apr; 12(2):e1184. PubMed ID: 38445541
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL‑112).
Sancho JM; Abrisqueta P; Kumar A; Cordoba R; Tani M; Langmuir P; Rappold E; Liu T; Lopez-Guillermo A
Leuk Lymphoma; 2024 Apr; ():1-11. PubMed ID: 38598516
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy.
Chari A; Munder M; Weisel K; Jenner M; Bygrave C; Petrucci MT; Boccadoro M; Cavo M; van de Donk NWCJ; Turgut M; Demirkan F; Karadogan I; Libby E; Kleiman R; Kuppens S; Bandekar R; Neff T; Heuck C; Qi M; Clemens PL; Goldschmidt H
Adv Ther; 2021 Feb; 38(2):1328-1341. PubMed ID: 33474705
[TBL] [Abstract][Full Text] [Related]
28. Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure-QTc in patients with advanced or refractory solid tumors.
Valade E; Dosne AG; Xie H; Kleiman R; Li LY; Perez-Ruixo JJ; Ouellet D
Cancer Chemother Pharmacol; 2019 Sep; 84(3):621-633. PubMed ID: 31280362
[TBL] [Abstract][Full Text] [Related]
29. Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies.
Swaisland H; Plummer R; So K; Garnett S; Bannister W; Fabre MA; Dota C; Fielding A
Cancer Chemother Pharmacol; 2016 Oct; 78(4):775-84. PubMed ID: 27553432
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the potential for QTc prolongation in patients with solid tumors receiving nivolumab.
Agrawal S; Waxman I; Lambert A; Roy A; Darbenzio R
Cancer Chemother Pharmacol; 2016 Mar; 77(3):635-41. PubMed ID: 26861469
[TBL] [Abstract][Full Text] [Related]
32. No effect of a single supratherapeutic dose of lersivirine, a next-generation nonnucleoside reverse transcriptase inhibitor, on corrected QT interval in healthy subjects.
Vourvahis M; Wang R; Ndongo MN; O'Gorman M; Tawadrous M
Antimicrob Agents Chemother; 2012 May; 56(5):2408-13. PubMed ID: 22371898
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid Tumors.
Ogasawara K; Xu C; Yin J; Darpo B; Carayannopoulos L; Xue H; Palmisano M; Krishna G
Clin Pharmacol Drug Dev; 2021 Apr; 10(4):366-375. PubMed ID: 32673446
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR.
Munasinghe WP; Mittapalli RK; Li H; Hoffman DM; Holen KD; Menon RM; Xiong H
Cancer Chemother Pharmacol; 2017 May; 79(5):915-922. PubMed ID: 28349167
[TBL] [Abstract][Full Text] [Related]
35. Exposure-QT analysis for sonidegib (LDE225), an oral inhibitor of the hedgehog signaling pathway, for measures of the QT prolongation potential in healthy subjects and in patients with advanced solid tumors.
Quinlan M; Zhou J; Hurh E; Sellami D
Eur J Clin Pharmacol; 2016 Dec; 72(12):1427-1432. PubMed ID: 27663457
[TBL] [Abstract][Full Text] [Related]
36. No QTc Prolongation With Zanubrutinib: Results of Concentration-QTc Analysis From a Thorough QT Study in Healthy Subjects.
Mu S; Darpo B; Tang Z; Novotny W; Tawashi M; Xue H; Willett M; Lin L; Sahasranaman S; Ou YC
Clin Transl Sci; 2020 Sep; 13(5):923-931. PubMed ID: 32144955
[TBL] [Abstract][Full Text] [Related]
37. Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer.
Borin MT; Chen M; Mocci S; Rubets I; Chittenden J; Aldairy W; Stroh M
Cancer Chemother Pharmacol; 2015 Feb; 75(2):401-10. PubMed ID: 25542267
[TBL] [Abstract][Full Text] [Related]
38. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
Becker A; Martin EC; Mitchell DY; Grenningloh R; Bender AT; Laurent J; Mackenzie H; Johne A
Clin Transl Sci; 2020 Mar; 13(2):325-336. PubMed ID: 31654487
[TBL] [Abstract][Full Text] [Related]
39. A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
Kelleher D; Tombs L; Preece A; Brealey N; Mehta R
Pulm Pharmacol Ther; 2014 Oct; 29(1):49-57. PubMed ID: 25020273
[TBL] [Abstract][Full Text] [Related]
40. Intravenous Amisulpride Does Not Meaningfully Prolong the QTc Interval at Doses Effective for the Management of Postoperative Nausea and Vomiting.
Fox GM; Albayaty M; Walker JL; Xue H; Darpo B
Anesth Analg; 2021 Jan; 132(1):150-159. PubMed ID: 31913911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
